Jason Gerberry
Stock Analyst at B of A Securities
(4.10)
# 532
Out of 5,118 analysts
169
Total ratings
61.48%
Success rate
9.42%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $25.00 | +12.00% | 5 | Dec 15, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $62 → $81 | $69.62 | +16.35% | 4 | Dec 9, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $86 → $97 | $79.98 | +21.28% | 7 | Dec 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $29 → $32 | $31.56 | +1.39% | 15 | Dec 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $230 → $247 | $170.50 | +44.87% | 6 | Nov 18, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $20.00 | +45.00% | 4 | Nov 13, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $26.81 | +19.38% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $25.61 | +17.14% | 6 | Aug 12, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $49 | $11.54 | +324.61% | 2 | Aug 12, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $173 → $176 | $150.68 | +16.80% | 6 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 → $1 | $2.20 | -54.55% | 4 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $34.75 | -33.81% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $45.37 | +1.39% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $46.57 | +194.18% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $12.37 | -19.16% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $24.06 | +24.69% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $65.16 | +53.47% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $8.41 | +185.37% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $33.12 | -6.40% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $3.41 | +16,029.03% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $28.01 | +3.53% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $44.33 | +26.33% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $37.91 | -20.87% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $100 → $50 | $8.78 | +469.48% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $1,078.73 | -53.65% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.38 | +552.17% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $7.11 | +251.62% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.82 | +174.73% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $7.13 | +278.68% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.34 | +1,392.54% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $8.19 | +1,121.00% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $230.84 | -58.85% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $54.11 | +10.89% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $106.62 | -15.59% | 11 | Oct 17, 2019 |
Pfizer
Dec 15, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $25.00
Upside: +12.00%
Arrowhead Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $62 → $81
Current: $69.62
Upside: +16.35%
Ionis Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $86 → $97
Current: $79.98
Upside: +21.28%
Teva Pharmaceutical Industries
Dec 9, 2025
Maintains: Buy
Price Target: $29 → $32
Current: $31.56
Upside: +1.39%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $230 → $247
Current: $170.50
Upside: +44.87%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $20.00
Upside: +45.00%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $26.81
Upside: +19.38%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $25.61
Upside: +17.14%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $11.54
Upside: +324.61%
Axsome Therapeutics
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $150.68
Upside: +16.80%
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.20
Upside: -54.55%
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $34.75
Upside: -33.81%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $45.37
Upside: +1.39%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $46.57
Upside: +194.18%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $12.37
Upside: -19.16%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $24.06
Upside: +24.69%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $65.16
Upside: +53.47%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $8.41
Upside: +185.37%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $33.12
Upside: -6.40%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $3.41
Upside: +16,029.03%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $28.01
Upside: +3.53%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $44.33
Upside: +26.33%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $37.91
Upside: -20.87%
Aug 8, 2023
Downgrades: Underperform
Price Target: $100 → $50
Current: $8.78
Upside: +469.48%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $1,078.73
Upside: -53.65%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.38
Upside: +552.17%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $7.11
Upside: +251.62%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.82
Upside: +174.73%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $7.13
Upside: +278.68%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.34
Upside: +1,392.54%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $8.19
Upside: +1,121.00%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $230.84
Upside: -58.85%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $54.11
Upside: +10.89%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $106.62
Upside: -15.59%